Risk factors of uncontrolled symptoms using the standard dose of second-generation H1 -antihistamines in chronic spontaneous urticaria childre

Not Applicable

Completed

• Conditions: second- risk factor; Chronic spontaneous urticaria; chronic spontaneous urticaria; antihistamines; generation H1 - uncontrolled symptoms; child

• Registration Number: TCTR20190720005
• Lead Sponsor: Faculty of Medicine, Songklanagarind Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2019-05-01
• Study Start: 2019-07-20
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 192

Inclusion Criteria

The CSU patients, who were diagnosed with chronic spontaneous urticaria and initially treated with the standard dose of second-generation H1 -antihistamine

Exclusion Criteria

The patients who had underlying diseases related to urticaria or angioedema such as maculopapular cutaneous mastocytosis, urticarial vasculitis, bradykinin-mediated angioedema or cryopyrin-associated periodic syndrome, and patients on immunosuppressive drugs

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
ncontrolled symptoms 4 weeks Clinical assessment by physician

Secondary Outcome Measures

Name	Time	Method
Treatment outcome until the patients can controlled symptoms Descriptive data